CareFusion (FRA:TCF) EPS Growth Rate (Future 3Y To 5Y Estimate) : 12.01 (As of Jun. 02, 2024)

View and export this data going back to . Start your Free Trial

What is CareFusion EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, CareFusion's EPS Growth Rate (Future 3Y To 5Y Estimate) is 12.01.

Competitive Comparison of CareFusion's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Medical Instruments & Supplies subindustry, CareFusion's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CareFusion's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CareFusion's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where CareFusion's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

CareFusion (FRA:TCF) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

CareFusion EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of CareFusion's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

CareFusion (FRA:TCF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CareFusion Corp (FRA:TCF) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CareFusion Corp a Delaware corporation was incorporated on January 14, 2009. It is a medical technology company. The Company offers a portfolio of products in the areas of medication management, infection prevention, operating room and procedural effectiveness, and respiratory care. Its primary product brands includes: Alaris intravenous (IV) infusion systems, Pyxis and Rowa automated medication dispensing and supply management systems, AVEA, Vela and LTV Series respiratory ventilators, ChloraPrep skin antiseptic products, MedMined data mining surveillance software and analytics, Vital Signs single-use consumables for respiratory care and anesthesiology, and Jaeger and SensorMedics cardiopulmonary diagnostic equipment. The Company operates in two business segments: Medical Systems and Procedural Solutions. In the Medical Systems segment, the Company develops, manufacture and market capital equipment and related supplies for medication management, which includes our infusion and medication dispensing technologies, supply management, as well as respiratory ventilation and diagnostic technologies. In the Procedural Solutions segment, the Company develops, manufacture and market single-use skin antiseptic and other patient-preparation products, specialty IV infusion valves, administration sets and accessories, IV catheters, IV drug preparation products, reusable surgical instruments, non-dedicated ventilator circuits and other disposables used for providing respiratory therapy, as well as single-use consumables for respiratory care and anesthesiology. The Company's competitors includes Baxter International; B. Braun; Fresenius Kabi; Hospira; Omnicell; McKesson; DrÃ¤ger; MAQUET, 3M; ICU Medical; Becton, Dickinson; Baxter International; B. Braun; Hospira; Smiths Medical; CR Bard; Integra Life Sciences; and Teleflex. The Company's operations are subject to the Federal Food, Drug and Cosmetic Act (FDC Act), as implemented and enforced by the United States Food and Drug Administration (FDA).